M&A Deal Summary

Crealta Pharmaceuticals Acquires Savient Pharmaceuticals

On December 11, 2013, Crealta Pharmaceuticals acquired life science company Savient Pharmaceuticals for 120M USD

Acquisition Highlights
  • This is Crealta Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Crealta Pharmaceuticals’ largest (disclosed) transaction.
  • This is Crealta Pharmaceuticals’ 1st transaction in the United States.
  • This is Crealta Pharmaceuticals’ 1st transaction in New Jersey.
Investment Fate
  • Savient Pharmaceuticals went bankrupt in 2014.

M&A Deal Summary
Date 2013-12-11
Target Savient Pharmaceuticals
Sector Life Science
Buyer(s) Crealta Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 120M USD

Target

Savient Pharmaceuticals

Bridgewater, New Jersey, United States
Savient Pharmaceuticals, Inc. is a biopharmaceutical company.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Crealta Pharmaceuticals

Glendale, Wisconsin, United States
Category Company
Founded 2013
Sector Life Science
DESCRIPTION

Crealta is a specialty pharmaceutical company focused on innovative therapeutics designed to improve patient outcomes. The company, which has two marketed medicines KRYSTEXXA and MIGERGOT, was formed to acquire, develop and market specialty medicines with a focus on select physician specialties.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-05-30 Savient Pharmaceuticals

Bridgewater, New Jersey, United States

Savient Pharmaceuticals, Inc. is a biopharmaceutical company.

Sell -
Mergr

Product

Company

Legal